Article Text

AB0361 Evaluation of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept or Tumor Necrosis Factor Inhibitors in Clinical Practice in Spain
  1. M.V. Hernández1,
  2. C.A. Sánchez-Piedra2,
  3. J.D. Cañete1,
  4. F. Sánchez-Alonso2,
  5. J. Manero-Ruiz3,
  6. A. Ortiz-García4,
  7. R. Rosello Pardo5,
  8. E. Pérez-Pampín6,
  9. C. Rodriguez-Lozano7,
  10. R. Sanmarti1,
  11. J.J. Gomez-Reino6,
  12. on behalf of BIOBADASER 2.0 Study Group
  1. 1Arthritis Unit. Rheumatology Dept., Hospital Clinic, Barcelona
  2. 2Research Unit, Spanish Society of Rheumatology, Madrid
  3. 3Rheumatology Dept., Hospital Universitario Miguel Servet, Zaragoza
  4. 4Rheumatology Dept., Hospital de la Princesa, Madrid
  5. 5Rheumatology Dept., Hospital General San Jorge, Huesca
  6. 6Rheumatology Dept., Hospital Clínico Universitario, Santiago de Compostela
  7. 7Rheumatology Dept., Hospital Dr. Negrín, Gran Canaria, Spain


Background Biological therapies have demonstrated efficacy in patients with rheumatoid arthritis (RA) improving the prognosis. The most widely used biological agents are tumor necrosis factor inhibitors (TNFi), although other biological agents with different mechanisms of actions, such abatacept, have been approved. Although all these drugs are indicated in RA, there is limited data on their use and whether differences in baseline characteristics of RA patients treated with different biologics

Objectives To analyze differences in baseline characteristics of RA patients treated with abatacept, a T-cell co-stimulation inhibitor, compared with those treated with a TNFi

Methods All BIOBADASER 2.0 register patients diagnosed with RA and treated with abatacept from January 2008 to December 2014 were selected. Baseline sociodemographic and clinical characteristics were analyzed compared them with RA patients treated with TNFi during the same period. Variables analyzed: age; gender; disease duration; positivity of rheumatoid factor; disease activity at initiation of biological measured by the DAS-28 score; number of previous biological agents (0, 1, ≥2); and concomitant glucocorticoid treatment. Differences between abatacept and TNFi patients in baseline DAS28 were analyzed according to the number of previous biological drugs received

Results From January 2008 to December 2014, 252 RA patients treated with abatacept and 640 with TNFi were included in the BIOBADASER 2.0 register. Baseline characteristics are shown in Table1. At baseline, patients treated with abatacept were significantly younger; had a longer disease duration; had received a greater number of previous biologics; and had a higher DAS-28 (significant in patients who had received 1 previous biologic) than those treated with TNFi

Conclusions Patients with RA treated with abatacept have more active disease and a poorer prognosis that those treated with TNFi, significantly longer disease duration, have failed more previous biological agents and have higher baseline inflammatory activity

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.